Page 105 - Human Use News Today

Investegate announcements from BioNTech SE, Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

Investegate announcements from Sanofi - Aventis Groupe, Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission

Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission First and only next-generation protein-based adjuvanted COVID-19 booster approved

Investegate announcements from GSK PLC, Sanofi-GSK COVID booster vaccine approved by EU

NEW YORK and MAINZ, GERMANY, November 10, 2022 - Pfizer Inc.(Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY Original/Omicron BA.4/BA.5

Recorded product revenue of $349.5 million for the third quarter, representing an 82% increase from $192.5 million in the prior-year period BRUKINSA product revenue totaled $155.5 million, increasing

This adapted COVID-19 vaccine targets both the original virus and the Omicron BA.4 and BA.5 sub-variants.

When COVID-19 broke out across the globe in 2020, Spain was hit especially hard, with an average of over 800 deaths a day at one point. Naturally, it fell to pharmaceutical companies to develop solutions which can cure the disease or alleviate its effects on patients. Many of these companies looked into drugs previously developed […]

Investegate announcements from BioNTech SE, BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update

The approval marks the second bright spot this week in scientists’ decades-long quest to blunt the damage wrought by RSV.